Entrada Therapeutics reports positive DMD trial results; Q1 Net Loss $39.7M
Entrada Therapeutics announced positive topline results from Cohort 1 of its ELEVATE-44-201 clinical study for Duchenne muscular dystrophy (DMD), demonstrating favorable safety, tolerability, and early functional benefits, including statistically significant improvement in Time to Rise velocity. The company reported $254.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026, with a cash runway expected into Q3 2027. For Q1 2026, Entrada reported a net loss of $39.7 million, an increase from $17.3 million in Q1 2025, primarily due to decreased collaboration revenue and increased R&D expenses for DMD programs. Entrada is on track to report additional clinical data for other DMD programs later in 2026.
Key Highlights
- ELEVATE-44-201 Cohort 1 topline results showed favorable safety, tolerability, and early functional benefit in DMD.
- ENTR-601-44 demonstrated statistically significant improvement in Time to Rise (TTR) velocity.
- Cash, cash equivalents, and marketable securities were $254.9 million as of March 31, 2026.
- Cash runway is expected into Q3 2027.
- Q1 2026 Collaboration Revenue was $0.9 million, down from $20.6 million in Q1 2025.
- Q1 2026 Research & Development expenses increased to $33.1 million from $32.1 million in Q1 2025.
- Q1 2026 Net Loss was $39.7 million, compared to $17.3 million in Q1 2025.
- ELEVATE-45-201 Cohort 1 data is on track for mid-2026, and ELEVATE-44-201 open-label and Cohort 2 data by year-end 2026.